Final Report of a Trial of Intensive versus Standard Blood-Pressure Control
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a previously reported randomized trial of standard and intensive systolic blood-pressure control, data on some outcome events had yet to be adjudicated and post-trial follow-up data had not yet been collected. METHODS: We randomly assigned 9361 participants who were at increased risk for cardiovascular disease but did not have diabetes or previous stroke to adhere to an intensive treatment target (systolic blood pressure, <120 mm Hg) or a standard treatment target (systolic blood pressure, <140 mm Hg). The primary outcome was a composite of myocardial infarction, other acute coronary syndromes, stroke, acute decompensated heart failure, or death from cardiovascular causes. Additional primary outcome events occurring through the end of the intervention period (August 20, 2015) were adjudicated after data lock for the primary analysis. We also analyzed post-trial observational follow-up data through July 29, 2016. RESULTS: At a median of 3.33 years of follow-up, the rate of the primary outcome and all-cause mortality during the trial were significantly lower in the intensive-treatment group than in the standard-treatment group (rate of the primary outcome, 1.77% per year vs. 2.40% per year; hazard ratio, 0.73; 95% confidence interval [CI], 0.63 to 0.86; all-cause mortality, 1.06% per year vs. 1.41% per year; hazard ratio, 0.75; 95% CI, 0.61 to 0.92). Serious adverse events of hypotension, electrolyte abnormalities, acute kidney injury or failure, and syncope were significantly more frequent in the intensive-treatment group. When trial and post-trial follow-up data were combined (3.88 years in total), similar patterns were found for treatment benefit and adverse events; however, rates of heart failure no longer differed between the groups. CONCLUSIONS: Among patients who were at increased cardiovascular risk, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and lower all-cause mortality than targeting a systolic blood pressure of less than 140 mm Hg, both during receipt of the randomly assigned therapy and after the trial. Rates of some adverse events were higher in the intensive-treatment group. (Funded by the National Institutes of Health; SPRINT ClinicalTrials.gov number, NCT01206062.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“From the first landmark 1967 Veterans Administration Cooperative Study2 to the 2021 SPRINT trial3, all outcome trials in hypertension have used the average of snapshot BP levels to demonstrate the efficacy of antihypertensive drug therapy in reducing cardiovascular events.”
From Blood pressure and its variability: classic and novel measurement techniques (2022) · cites this paper as [3]
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Self-citationCox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationThe J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
A stagewise rejective multiple test procedure based on a modified Bonferroni test
HOMMEL, G. (1988) · Biometrika · doi:10.1093/biomet/75.2.383 · Cited by 1,367
Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease
Appel, L. J., Wright, J. T., Greene, T., Agodoa, L. Y., Astor, B. C., Bakris, G. L., Cleveland, W. H., Charleston, J., Contreras, G., Faulkner, M. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910975 · Cited by 719
Ambrosius, W. T., Sink, K. M., Foy, C. G., Berlowitz, D. R., Cheung, A. K., Cushman, W. C., Fine, L. J., Goff, D. C., Johnson, K. C., Killeen, A. A., et al. (2014) · Clinical Trials · doi:10.1177/1740774514537404 · Cited by 544
Holtkamp, F. A., de Zeeuw, D., Thomas, M. C., Cooper, M. E., de Graeff, P. A., Hillege, H. J. L., Parving, H.-H., Brenner, B. M., Shahinfar, S., & Lambers Heerspink, H. J. (2011) · Kidney International · doi:10.1038/ki.2011.79 · Cited by 364
Cited by
The Global Burden of Cardiovascular Diseases and Risk
Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V., & Roth, G. A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.005 · Cited by 2,217
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension
Zhang, W., Zhang, S., Deng, Y., Wu, S., Ren, J., Sun, G., Yang, J., Jiang, Y., Xu, X., Wang, T.-D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2111437 · Cited by 784
Treatment of hypertension: a review
Carey, R. M., Moran, A. E., & Whelton, P. K. (2022) · JAMA · doi:10.1001/jama.2022.19590 · Cited by 455
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 310
European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics
Timmis, A., Aboyans, V., Vardas, P., Townsend, N., Torbica, A., Kavousi, M., Boriani, G., Huculeci, R., Kazakiewicz, D., Scherr, D., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae466 · Cited by 314
Blood pressure and its variability: classic and novel measurement techniques
Schutte, A. E., Kollias, A., & Stergiou, G. S. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00690-0 · Cited by 335
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001356 · Cited by 213
Sex differences in the prevalence, outcomes and management of hypertension
Connelly, P. J., Currie, G., & Delles, C. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01183-8 · Cited by 320
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
Bi, Y., Li, M., Liu, Y., Li, T., Lu, J., Duan, P., Xu, F., Dong, Q., Wang, A., Wang, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2412006 · Cited by 268
Ma, J., Li, Y., Yang, X., Liu, K., Zhang, X., Zuo, X., Ye, R., Wang, Z., Shi, R., Meng, Q., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01430-7 · Cited by 243
Liu, J., Li, Y., Ge, J., Yan, X., Zhang, H., Zheng, X., Lu, J., Li, X., Gao, Y., Lei, L., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01028-6 · Cited by 258
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
Hypertension management in patients with cardiovascular comorbidities
Lauder, L., Mahfoud, F., Azizi, M., Bhatt, D. L., Ewen, S., Kario, K., Parati, G., Rossignol, P., Schlaich, M. P., Teo, K. K., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac395 · Cited by 210
Sun, Y., Mu, J., Wang, D. W., Ouyang, N., Xing, L., Guo, X., Zhao, C., Ren, G., Ye, N., Zhou, Y., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00325-7 · Cited by 164
Chow, C. K., Atkins, E. R., Hillis, G. S., Nelson, M. R., Reid, C. M., Schlaich, M. P., Hay, P., Rogers, K., Billot, L., Burke, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01922-x · Cited by 159
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 196
Canoy, D., Nazarzadeh, M., Copland, E., Bidel, Z., Rao, S., Li, Y., & Rahimi, K. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01706-4 · Cited by 163
World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update
Laranjo, L., Lanas, F. T., Sun, M. C., Chen, D. A., Hynes, L., Imran, T. F., Kazi, D. S., Kengne, A. P., Komiyama, M., Kuwabara, M., et al. (2024) · Global Heart · doi:10.5334/gh.1278 · Cited by 166
Nakano, S., Kohsaka, S., Chikamori, T., Fukushima, K., Kobayashi, Y., Kozuma, K., Manabe, S., Matsuo, H., Nakamura, M., Ohno, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-21-1041 · Cited by 146
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study
Razo, C., Welgan, C. A., Johnson, C. O., McLaughlin, S. A., Iannucci, V., Rodgers, A., Wang, N., LeGrand, K. E., Sorensen, R. J. D., He, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01974-1 · Cited by 109
Brazilian Guidelines of Hypertension – 2025
Brandão, A. A., Rodrigues, C. I. S., Bortolotto, L. A., Armstrong, A. D. C., Mulinari, R. A., Feitosa, A. D. M., Gomes, M. A. M., Barbosa, E. C. D., Moura-Neto, J. A., Neves, M. F., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250624 · Cited by 156
Phenotyping the hypertensive heart
Tadić, M., Cuspidi, C., & Marwick, T. H. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac393 · Cited by 108
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 159
Normal‐tension glaucoma: Current concepts and approaches‐A review
Leung, D. Y. L., & Tham, C. C. (2022) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.14043 · Cited by 99
Advances in the management of chronic kidney disease
Chen, T. K., Hoenig, M. P., Nitsch, D., & Grams, M. E. (2023) · BMJ · doi:10.1136/bmj-2022-074216 · Cited by 122
Hypertension in chronic kidney disease—treatment standard 2023
Georgianos, P. I., & Agarwal, R. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad118 · Cited by 116
Hypertension and Heart Failure: From Pathophysiology to Treatment
Gallo, G., & Savoia, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126661 · Cited by 112
Ohya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 107
Cardiovascular Considerations After Cancer Therapy
Blaes, A. H., Nohria, A., Armenian, S. H., Bergom, C. R., Thavendiranathan, P., Barac, A., Sanchez‐Petitto, G., Desai, S., Zullig, L. L., Morgans, A. K., et al. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.06.006 · Cited by 100
Khan, S. S., Breathett, K., Braun, L. T., Chow, S. L., Gupta, D. K., Lekavich, C., Lloyd-Jones, D. M., Ndumele, C. E., Rodriguez, C. J., Allen, L. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001307 · Cited by 75
“In addition to SPRINT, several other RCTs have demonstrated that intensive BP lowering reduces MACEs, which is largely driven by the prevention of HF. 98,100,101 The absolute benefit for BP lowering is directly proportional to the baseline predicted risk and magnitude of BP lowering.”
Jaeger, B. C., Bress, A. P., Bundy, J. D., Cheung, A. K., Cushman, W. C., Drawz, P. E., Johnson, K. C., Lewis, C. E., Oparil, S., Rocco, M. V., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.3345 · Cited by 72
Qiu, Y., Xu, S., Chen, X., Wu, X., Zhou, Z., Zhang, J., Tu, Q., Dong, B., Liu, Z., He, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01577-3 · Cited by 75
Oikonomou, E. K., Spatz, E. S., Suchard, M. A., & Khera, R. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00170-4 · Cited by 71
Optimal Antihypertensive Systolic Blood Pressure: A Systematic Review and Meta-Analysis
Whelton, P. K., O’Connell, S. S., Mills, K. T., & He, J. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.23597 · Cited by 76
Chen, T., Shao, F., Chen, K., Wang, Y., Wu, Z., Wang, Y., Gao, Y., Cornelius, V. R., Li, C., & Jiang, Z. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.1657 · Cited by 75
Nwia, S. M., Leite, A. P. D. O., Li, X. C., & Zhuo, J. L. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1198090 · Cited by 76
Goupil, R., Tsuyuki, R. T., Santesso, N., Terenzi, K. A., Habert, J., Cheng, G., Gysel, S. C., Bruneau, J., Leung, A. A., Campbell, N. R. C., et al. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.241770 · Cited by 60
The Burden of Resistant Hypertension Across the World
Brant, L. C. C., Passaglia, L. G., Filho, M. M. P., de Castilho, F. M., Ribeiro, A. L. P., & Nascimento, B. R. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01173-w · Cited by 70
Inoue, K., Athey, S. C., & Tsugawa, Y. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad037 · Cited by 61
Cuffless Blood Pressure in clinical practice: challenges, opportunities and current limits.
Henry, B., Merz, M., Hoang, H., Abdulkarim, G., Wosik, J., & Schoettker, P. (2024) · Blood Pressure · doi:10.1080/08037051.2024.2304190 · Cited by 63
Drawz, P. E., Beddhu, S., Bignall, O. N. R., Cohen, J. B., Flynn, J. T., Ku, E., Rahman, M., Thomas, G., Weir, M. R., & Whelton, P. K. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.013 · Cited by 57
Hypotension as a marker or mediator of perioperative organ injury: a narrative review
Ackland, G. L., & Abbott, T. E. F. (2022) · British Journal of Anaesthesia · doi:10.1016/j.bja.2022.01.012 · Cited by 56
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 65
Guo, X., Sun, G., Xu, Y., Zhou, S., Song, Q., Li, Y., Ouyang, N., Li, G., Cheng, Z., Ye, N., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01391-1 · Cited by 55
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 60
Unique characteristics of Asians with hypertension: what is known and what can be done?
Loo, G. J. M., Puar, T. H. K., Foo, R., Ong, T. K., Wang, T., Nguyen, Q. N., Chin, C. T., & Chin, C. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003706 · Cited by 43
Hypertension, coronary artery disease and myocardial ischemic syndromes
Volpe, M., & Gallo, G. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107230 · Cited by 44
Sanchez, R. A., Coca, A., Molina, D. I., Alcocer, L. A., Aristizábal, D., Barbosa, E. C. D., Brandão, A. A., Diaz-Velazco, M. E., Hernández-Hernández, R., López-Jaramillo, P. A., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003899 · Cited by 52
Fujii, M., Ohno, Y., Ikeda, A., Godai, K., Li, Y., Nakamura, Y., Yabe, D., Tsushita, K., Kashihara, N., Kamide, K., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01185-2 · Cited by 42
Huang, Y., Meng, L., Liu, C., Liu, S., Tao, L., Zhang, S., Gao, J., Sun, L., Qin, Q., Zhao, Y., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac273 · Cited by 36
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond
Christensen, B. W., Zaha, V. G., & Awan, F. T. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2067526 · Cited by 35
Thapa, R., Zengin, A., Neupane, D., Mishra, S. R., Koirala, S., Kallestrup, P., & Thrift, A. G. (2023) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00214-0 · Cited by 36
Clinical trials in vascular cognitive impairment following SPRINT-MIND: An international perspective
Elahi, F. M., Alladi, S., Black, S. E., Claassen, J. A. H. R., DeCarli, C. S., Hughes, T. M., Moonen, J. E. F., Pajewski, N. M., Price, B. R., Satizábal, C. L., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101089 · Cited by 39
Hypertension Across a Woman’s Life Cycle
Ghazi, L., Annabathula, R. V., Bello, N. A., Zhou, L., Stacey, R. B., & Upadhya, B. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01230-4 · Cited by 40
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
Ostrominski, J. W., CHENG, A. Y. Y., Nelson, A. J., Neuen, B. L., Sattar, N. A., Tuttle, K. R., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01384-4 · Cited by 35
STEP to blood pressure management of elderly hypertension: evidence from Asia
Zhang, W., & Cai, J. (2022) · Hypertension Research · doi:10.1038/s41440-022-00875-7 · Cited by 34
Zhang, M., Wu, J., Wang, Y., Wu, J., Hu, W., Jia, H., & Sun, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16830 · Cited by 39
Acharya, S., Neupane, G., Seals, A. L., Madhav, K. C., Giustini, D., Sharma, S. P., Taylor, Y. J., Palakshappa, D., Williamson, J. D., Moore, J. B., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.22109 · Cited by 33
Zhou, L., He, L., Kong, Y., Lai, Y., Dong, J., & Ma, C. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14690 · Cited by 36
The Promise and Illusion of Continuous, Cuffless Blood Pressure Monitoring
Hu, J., Park, D. Y., Agarwal, N., Herzig, M. S., Ormseth, G., Kaushik, M., Giao, D. M., Turkson‐Ocran, R., & Juraschek, S. P. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01932-4 · Cited by 33
Satoh, M., Muroya, T., Murakami, T., Obara, T., Asayama, K., Ohkubo, T., Imai, Y., & Metoki, H. (2023) · Hypertension Research · doi:10.1038/s41440-023-01452-2 · Cited by 31
Blood pressure targets in CKD 2021: the never-ending guidelines debacle
Carriazo, S. M., Sarafidis, P. A., Ferro, C. J., & Ortíz, A. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac014 · Cited by 32
SPRINT Revisited: Updated Results and Implications
Wright, J. T., Whelton, P. K., Johnson, K., Snyder, J. K., Reboussin, D. M., Cushman, W. C., Williamson, J. D., Pajewski, N. M., Cheung, A. K., Lewis, C. E., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17682 · Cited by 31
Elucidating the complex interplay between chronic kidney disease and hypertension
Nagata, D., & Hishida, E. (2024) · Hypertension Research · doi:10.1038/s41440-024-01937-8 · Cited by 34
An, S., Teo, K. Y. C., McConnell, M. V., Marshall, J., Galloway, C., & Squirrell, D. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101352 · Cited by 31
Lee, H., Lee, H., Cho, S. M. J., Kim, D., Park, S., & Kim, H. C. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.015 · Cited by 29
Snyman, J. R., Bortolotto, L. A., Esposti, L. D., Jayagopal, P. B., Конради, А. О., Perrone, V., & Borghi, C. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003570 · Cited by 30
Shakil, S. S., Ojji, D. B., Longenecker, C. T., & Roth, G. A. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.009046 · Cited by 26
Simonenko, M., Hansen, D., Niebauer, J., Volterrani, M., Adamopoulos, S. N., Amarelli, C., Ambrosetti, M., Anker, S. D., Bayés‐Genís, A., Gal, T. B., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae179 · Cited by 34
Lauder, L., Weber, T., Böhm, M., Brouwers, S., Bruno, R. M., Gerdts, E., Kreutz, R. H., Lüscher, T. F., Mancia, G., McEvoy, J. W., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01187-2 · Cited by 30
What Level of Blood Pressure Is Concerning in Childhood?
Flynn, J. T. (2022) · Circulation Research · doi:10.1161/circresaha.121.319819 · Cited by 25
Reboldi, G., Angeli, F., Gentile, G., & Verdecchia, P. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.03.032 · Cited by 28
The Role of Vascular Risk Factors in Cognitive Impairment and Dementia and Prospects for Prevention
Mahinrad, S., Sorond, F. A., & Gorelick, P. B. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.07.007 · Cited by 25
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 33
Continuity of Care and the Control of High Blood Pressure at Colombian Primary Care Services
Barrera, L., Oviedo, D. G., Silva, Á., Tovar, D., & Méndez, F. (2021) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580211047043 · Cited by 25
Blood Pressure Intervention and Control in SPRINT
Cushman, W. C., Ringer, R. J., Rodríguez, C. J., Evans, G. W., Bates, J. T., Cutler, J. A., Hawfield, A. T., Kitzman, D. W., Nasrallah, I. M., Oparil, S., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.17233 · Cited by 23
Chiu, N., Chiu, L., Aggarwal, R., Raber, I., Bhatt, D. L., & Mukamal, K. J. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19882 · Cited by 24
Definition, prevalence, and economic impacts of hypertension on the elderly population
Lien, C.-W., Lee, Y., Lu, C., Chang, Y.-C., Lin, Y., Cheng, H., Chen, M. Y., Lee, L., Huang, C.-K., Lin, Y., et al. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.02.020 · Cited by 26
2023 Guideline for the management of hypertension in the elderly population in China
Hua, Q., Fan, L., Wang, Z., & Li, J. (2024) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2024.06.001 · Cited by 23
Kiernan, M., & Baiocchi, M. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac019 · Cited by 22
Hamann, G. F., Sander, D., Grau, A., & Röther, J. (2022) · DGNeurologie · doi:10.1007/s42451-022-00461-8 · Cited by 41
Ablation of Prdm16 and beige fat identity causes vascular remodeling and elevated blood pressure
Koenen, M., Becher, T., Pagano, G., Gaudio, I. D., Barrero, J. A., Montezano, A. C. I., Ortiz, J. R., Lin, Z., Gómez-Banoy, N., Amblard, R., et al. (2026) · Science · doi:10.1126/science.ady8644 · Cited by 23
Nolde, J. M., Beaney, T. E., Carnagarin, R., Schutte, A. E., Poulter, N. R., & Schlaich, M. P. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19144 · Cited by 22
Cohen, J. B., Marcum, Z. A., Zhang, C., Derington, C. G., Greene, T., Ghazi, L., Herrick, J. S., King, J. B., Cheung, A. K., Bryan, R. N., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.20680 · Cited by 23
Yu, G., Cheng, J., Jiang, Y., Li, H., Li, X., & Chen, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.813603 · Cited by 20
Brain bioenergetics in chronic hypertension: Risk factor for acute ischemic stroke
Ferrari, F., & Villa, R. F. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115260 · Cited by 23
Interventions for reducing blood pressure in prehypertension: A meta-analysis
Li, W., Liu, H., Wang, X., Liu, J., Xiao, H., Wang, C., & Wu, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1139617 · Cited by 20
Drawz, P. E., Lenoir, K. M., Rai, N. K., Rastogi, A., Chu, C. D., Rahbari-Oskoui, F. F., Whelton, P. K., Thomas, G., McWilliams, A. D., Agarwal, A. K., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000335 · Cited by 25
Haze, T., Katsurada, K., Sakata, S., Kuwabara, M., Nishida, N., Azegami, T., Sakima, A., & Kai, H. (2025) · Hypertension Research · doi:10.1038/s41440-025-02131-0 · Cited by 24
Park, C. H., Kim, H. W., Joo, Y. S., Park, J. T., Chang, T. I., Yoo, T., Park, S. K., Chae, D., Chung, W., Kim, Y., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025513 · Cited by 21
Satoh, M., Hirose, T., Satoh, H., Nakayama, S., Obara, T., Murakami, T., Muroya, T., Asayama, K., Kikuya, M., Mori, T., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003186 · Cited by 17
Lee, J. Y., Bak, J. K., Kim, M., Shin, H. G., Park, K., Lee, S., Lee, H., Lee, J.-Y., Kim, K.-I., Kang, S., et al. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.249 · Cited by 20
The lowest well tolerated blood pressure: A personalized target for all?
Verdecchia, P., Angeli, F., & Reboldi, G. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.025 · Cited by 18
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
Impact of Antihypertensive Drug Class on Outcomes in SPRINT
DeCarolis, D. D., Gravely, A., Olney, C. M., & Ishani, A. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18369 · Cited by 17
Metadata
- Authors
- The SPRINT Research Group
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- The SPRINT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-20
- Volume
- 384
- Issue
- 20
- Pages
- 1921-1930
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9907774
- OpenAlex
- W3161638097
- Cited by
- 454
- References
- 20
- Citations by year
- 2026: 74 · 2025: 92 · 2024: 74 · 2023: 83 · 2022: 105 · 2021: 26
- FWCI
- 48.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health, National Heart, Lung, and Blood Institute
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
- NIH, National Institute on Aging
- NIH, National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, major adverse cardiovascular events, all-cause mortality, cardiovascular risk, adverse events, acute kidney injury, heart failure, post-trial follow-up, SPRINT trial, acute coronary syndrome, stroke, myocardial infarction, syncope, electrolyte imbalance, hypotension
- MeSH terms
- Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.